Mitoxantrone liposomal - CSPC ZhongQi Pharmaceutical Technology Co.

Drug Profile

Mitoxantrone liposomal - CSPC ZhongQi Pharmaceutical Technology Co.

Alternative Names: 2010L04017; Mitoxantrone hydrochloride liposome injection

Latest Information Update: 05 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CSPC ZhongQi Pharmaceutical Technology
  • Class Anthraquinones; Antineoplastics
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Breast cancer; Cutaneous T cell lymphoma; Diffuse large B cell lymphoma; Peripheral T-cell lymphoma
  • Phase I/II Non-Hodgkin's lymphoma
  • No development reported Solid tumours

Most Recent Events

  • 23 May 2017 CSPC ZhongQi Pharmaceutical Technology terminates a phase-II trial in Cutaneous T-cell lymphoma (Second-line therapy or greater) in China (IV) (NCT02597153)
  • 22 May 2017 CSPC ZhongQi Pharmaceutical Technology withdraws prior to enrolment a phase-I trial in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater, Late-stage disease) in China (IV) (NCT02595242)
  • 02 Aug 2016 CSPC ZhongQi Pharmaceutical Technology plans a phase I/II trial in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (NCT02856685)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top